One thesis, from inception to liquidity
The wave is the same everywhere; how we back it differs.
In the United States and Europe we invest at inception. Through Liquidity Solutions, we bring the same scientific underwriting to positions that already exist. Different entry points, one point of view.
US Venture
We invest in US companies whose edge is scientific, in the world’s deepest biotech ecosystem, and stay close as the science resolves.
Europe Venture
Our European team builds companies from world-class research, with direct access to Tachyon’s US network from day one.
Liquidity Solutions
Secondary and liquidity investments in private biotech companies, funds and portfolios, primarily in the US.
Why one firm runs venture and liquidity
Scientific Risk-Arbitrage: capital that cannot assess the science tends to discount or avoid it. We can, so we underwrite it directly – at inception in the US and Europe, and later in a company’s life through Liquidity Solutions.
The entry point changes. The underwriting doesn’t.
Building a biotech company, or considering liquidity in one?
Venture and liquidity visitors need different doors. Pick yours.